Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): the Effects of D2 Antagonism on Candidate Endophenotypes [SUBSTUDY OF 700191486]

Trial Profile

Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): the Effects of D2 Antagonism on Candidate Endophenotypes [SUBSTUDY OF 700191486]

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Amisulpride (Primary)
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Pharmacodynamics
  • Acronyms OPTiMiSE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Oct 2016 Status changed from recruiting to completed.
    • 15 Dec 2015 Planned End Date changed from 1 Jan 2016 to 1 Jun 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top